###### Strengths and limitations of this study

-   This study adds to the knowledge base regarding the level of evidence used to support decisions to remove drug products from the market.

-   Results of this research are in line with the findings of other study groups which concluded that there has been a shift in the level of evidence used, for example, results of randomised controlled trials and cohort studies are used to justify a product withdrawal.

-   English and French websites and publications were only searched.

-   The international non-proprietary name of each drug was included in the PubMed search strategy but as various drug names exist for the same compound, a potential exists for the exclusion of some publications from contributing evidence.

Introduction {#s1}
============

The decision to remove a drug product from the market is not taken lightly either by the regulatory authority or the marketing authorisation holder. A number of reasons contribute to the withdrawal such as the emergence of new safety evidence and significant drug interactions. Ultimately, the risk-benefit balance is paramount when making such decisions. The regulatory authorities review the evidence, such as spontaneous case reports or results from a randomised controlled trial (RCT) and prepare an opinion on whether the marketing authorisations of medicinal products containing that particular drug should be maintained, changed, suspended or withdrawn. The interpretation of the available safety data by the numerous competent authorities across the European Union (EU) is wide ranging as is the accessibility of information regarding how they reach their conclusion.

In 2005, legislation was introduced to ensure marketing authorisation holders complete a risk management plan (RMP) for their newly licensed product incorporating, where appropriate, post-marketing safety surveillance studies in the general population with regular assessment and appropriate reporting to the CHMP.[@R1] The aim of the RMP is to ensure a more proactive approach to pharmacovigilance by putting in place measures that allow for the early detection and minimisation of risks throughout a medicine's lifecycle. This should, in theory, result in a reduction in the length of time for drug withdrawal should a safety issue arise. Risk management planning in the EU has been further enhanced by the introduction of new EU legislation for good pharmacovigilance practices which became applicable in July 2012.[@R2]

Previous studies looked at the type of evidence used to support the withdrawal of products, for safety reasons, in different individual countries and over varying time periods. Arnaiz *et al*[@R3] reported on products withdrawn in Spain between 1990 and 1999, Clarke *et al*[@R4] for products in the USA and the UK from 1999 to 2001 and Olivier and Montastruc[@R5] for medicines in France from 1998 to 2004. They all concluded that case reports were the mainstay of evidence used to support withdrawal decisions for pharmacovigilance reasons; case--control studies, cohort studies and RCTs were used as evidence in less than one-third of decisions. Paludetto *et al*[@R6] revisited the issue 6 years later, between 2005 and 2011, and reported a shift in the level of evidence used. They determined that, of the 22 active substances withdrawn from the French market within this 6-year time frame, 68% of the decisions used multiple sources of evidence including clinical trials and pharmacoepidemiological studies. The objective of this study was to explore the level of evidence used to support the withdrawal of marketing authorisation of drug products in the time period 2002--2011 in the EU as a whole.

Methods {#s2}
=======

Drug products withdrawn from the EU market for safety or pharmacovigilance reasons, either by a medicines agency or a marketing authorisation holder, during the period 2002--2011 were identified. This was established by carrying out detailed searches on the websites of the WHO, the European Medicines Agency (EMA) and those of national medicines agencies throughout the EU plus Norway, Iceland and Liechtenstein. The WHO Pharmaceutical Newsletter and the EMA press releases provided the most useable information. In addition, pharmaceutical companies were contacted to obtain more information concerning dates of withdrawal in specific countries.

Prescription and over-the-counter products were included if their marketing authorisation was withdrawn or suspended due to any safety reason such as an adverse drug reaction, abuse or misuse. Active ingredients contained in a combination product were also included. Veterinary products, herbal drugs, vaccines, excipients, biological drugs, radiopharmaceuticals products and diagnostic agents were excluded. Drugs were not included if only one particular dose, dosage form or indication was withdrawn.

The scientific evidence leading to the withdrawal decision was identified from a search within PubMed, the EMA website (published documents searched included: 'Press releases', 'Questions and Answers' and 'Scientific conclusions') and national medicines agencies websites. Within the 'Questions and Answers' reports and 'Press releases', prepared by the EMA, a summary of the reviewed evidence with reference to study type (eg, RCT, animal study) is often included. A request was also submitted to the EMA for information on the number of cases entered into EudraVigilance related to the reason of withdrawal for each drug.

A search strategy was developed in PubMed by first, searching under the International Non-proprietary Name (INN) of the drug. Second, if over 200 publications were found, the INN combined with the MeSH term describing the pharmacovigilance problem was entered. Third, the INN combined with the terms 'adverse drug reaction', 'adverse event', 'toxicity' and 'poisoning' was used. Furthermore, articles published up to 1 year after the drug withdrawals were included to account for the potential delay between the end of a study and its publication.

Data were collated from these sources and a comprehensive literature review was conducted. However, a fully systematic review was not carried out due to time and resource constraints. Any evidence cited in these sources was categorised according to study design including animal studies, case reports (including spontaneous case reports, published case reports and case series), case--control studies, cohort studies, RCTs, meta-analyses and other studies (including clinical trials not randomised and/or not controlled and incidence studies). Only studies where statistically significant results were found were included.

Results {#s3}
=======

Nineteen drugs were withdrawn for pharmacovigilance reasons in the EU from 2002 to 2011 ([table 1](#BMJOPEN2013004221TB1){ref-type="table"}). The anatomical therapeutic chemical classes of drugs most represented in the nineteen drugs withdrawn are 'nervous system' (5/19 analgesics, antidepressants, antipsychotics and hypnotics), 'musculoskeletal system' (5/19 non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants) and 'alimentary tract and metabolism' (4/19 antidiabetics and antiobesity drugs).

###### 

List of drugs withdrawn for safety reasons in all EU member states between 2002 and 2011 grouped by adverse drug reaction or safety concern

  Drug name                                     Drug class or use                                                   Year first marketed   Year of withdrawal   Length of time on market (years)   Adverse reaction or safety concern
  --------------------------------------------- ------------------------------------------------------------------- --------------------- -------------------- ---------------------------------- ------------------------------------------------------------
  Rofecoxib                                     NSAID (COX-2 inhibitor)                                             1999                  2004                 5                                  Thrombotic events
  Thioridazine                                  Neuroleptic (α-adrenergic and dopaminergic receptor antagonist)     1958                  2005                 47                                 Cardiac disorders
  Valdecoxib                                    NSAID (COX-2 inhibitor)                                             2003                  2005                 2                                  Cardiovascular and cutaneous disorders
  Rosiglitazone                                 Antidiabetic treatment (PPAR agonist)                               2000                  2010                 10                                 Cardiovascular disorders
  Sibutramine                                   Treatment of obesity (serotonin-noradrenaline reuptake inhibitor)   1999                  2010                 11                                 Cardiovascular disorders
  Orciprenaline                                 Sympathomimetic (non-specific β-agonist)                            1961                  2010                 49                                 Cardiac disorders
  Benfluorex                                    Anorectic and hypolipidaemic                                        1974                  2009                 35                                 Heart valve disease---Pulmonary hypertension
  Clobutinol                                    Cough suppressant (centrally acting)                                1961                  2007                 46                                 QT prolongation
  Buflomedil                                    Vasodilator (α1 and α2 receptor antagonist)                         1974                  2011                 37                                 Neurological and cardiac disorders (sometimes fatal)
  Veralipride                                   Neuroleptic (and dopaminergic receptor antagonist)                  1979                  2007                 28                                 Neurological and psychiatric disorders
  Rimonabant                                    Treatment of obesity (cannabinoid receptor antagonist)              2006                  2008                 2                                  Psychiatric disorders
  Carisoprodol                                  Muscle relaxant                                                     1959                  2007                 48                                 Intoxication---Psychomotor impairment---Addiction---misuse
  Aceprometazine + Acepromazine + Clorazepate   Hypnotic                                                            1988                  2011                 23                                 Cumulative adverse effects---misuse---fatal side effect
  Dextropropoxyphene                            Opioid painkiller                                                   ∼1960                 2009                 49                                 Fatal overdose
  Nefazodone                                    Antidepressant                                                      1994                  2003                 9                                  Hepatotoxicity
  Ximelagatran/melagatran                       Anticoagulant (thrombin inhibitor)                                  2003                  2006                 3                                  Hepatotoxicity
  Lumiracoxib                                   NSAID (COX-2 inhibitor)                                             2003                  2007                 4                                  Hepatotoxicity
  Sitaxentan                                    Antihypertensive (endothelin receptor antagonist)                   2006                  2010                 4                                  Hepatotoxicity
  Bufexamac                                     NSAID                                                               ∼1970                 2010                 40                                 Contact allergic reactions

EU, European Union; NSAID, non-steroidal anti-inflammatory drug.

The median time to withdrawal was 23 years with an IQR of 4 and 46 ([table 1](#BMJOPEN2013004221TB1){ref-type="table"}).

Case reports were cited in 95% of withdrawals (18/19) and case--control studies (4/19), cohorts studies (4/19), RCTs (12/19) and meta-analysis (5/19) were cited in 63% of withdrawals (12/19; [table 2](#BMJOPEN2013004221TB2){ref-type="table"}).

###### 

List of evidence used to support medicinal product withdrawals in all EU member states between 2002 and 2011 derived from EMA reports, PubMed literature search and websites of competent authorities

  Drug name                                 Case reports   Animal studies   Case--control   Cohort   RCTs   Meta-analysis   \*Others
  ----------------------------------------- -------------- ---------------- --------------- -------- ------ --------------- ----------
  Rofecoxib                                 X                               x               x        x      X               
  Thioridazine                              X              X                x                        x      X               
  Valdecoxib                                X                                                        x      X               
  Rosiglitazone                             X                               x               x        x      X               
  Sibutramine                               X                                                        x                      x
  Orciprenaline                             X                                                        x                      
  Benfluorex                                X                               x               x        x                      
  Clobutinol                                X              X                                         x                      
  Buflomedil                                X              X                                                                
  Veralipride                               X                                                                               
  Rimonabant                                X                                                        x      X               
  Carisoprodol                              X              X                                x        x                      x
  Aceprometazine+Acepromazine+Clorazepate   X                                                                               x
  Dextropropoxyphene                        X                                                                               x
  Nefazodone                                X                                                                               x
  Ximelagatran/melagatran                                                                            x                      
  Lumiracoxib                               X                                                        x                      
  Sitaxentan                                X              X                                                                
  Bufexamac                                 X              X                                                                x

\*Other studies include non-randomised and/or not controlled clinical trials and incidence studies.

EMA, European Medicines Agency; EU, European Union.

Cardiovascular events or disorders were the main reason for withdrawal (9/19), followed by hepatic disorders (4/19) and neurological or psychiatric disorders (4/19).

A list of the adverse drug reactions reported in EudraVigilance, correlating to the safety issue given as the reason for withdrawal for each drug product is shown in [table 3](#BMJOPEN2013004221TB3){ref-type="table"}. No results were returned for ximelagatran/melagatran on querying the database for hepatotoxicity reports which is in line with the EMA assessment which states that an RCT (EXTEND) study[@R7] elucidated this safety concern.[@R8] A high number of reports were recorded for rosiglitazone; 10 834 cases of cardiac disorders associated with its use.

###### 

Count of case reports of selected withdrawn drug products submitted to EudraVigilance up to 30 June 2012

  Drug name                                  MedDRA level                                  Term                                     Total
  ------------------------------------------ --------------------------------------------- ---------------------------------------- --------
  Rofecoxib                                  PT                                            Myocardial infarction                    6711
  Thioridazine                               HLGT                                          Cardiac arrhythmias                      179
  PT                                         Sudden death                                  28                                       
  Valdecoxib\*                               SOC                                           Skin and subcutaneous tissue disorders   317
  SOC                                        Cardiac disorders                             313                                      
  Rosiglitazone\*                            SOC                                           Cardiac disorders                        10 834
  Sibutramine                                PT                                            Blood pressure increased                 69
  PT                                         Heart rate increased                          23                                       
  Orciprenaline                              HLGT                                          Cardiac arrhythmias                      15
  Benfluorex                                 HLGT                                          Cardiac valve disorders                  3439
  PT                                         Pulmonary hypertension                        181                                      
  Clobutinol                                 HLGT                                          Cardiac arrhythmias                      14
  Buflomedil                                 HLGT                                          Cardiac arrhythmias                      36
  HLGT                                       Fatal outcomes†                               14                                       
  HLGT                                       Seizures (including subtypes)                 35                                       
  Veralipride                                HLGT                                          Anxiety disorders and symptoms           142
  HLT                                        Depressive disorders                          221                                      
  Rimonabant\*                               SOC                                           Psychiatric disorders                    918
  PT                                         Depression                                    545                                      
  Carisoprodol                               HLGT                                          Mental impairment disorders              18
  HLGT                                       Movement disorders (including parkinsonism)   15                                       
  Aceprometazine+Acepromazine+ Clorazepate   HLGT                                          Fatal outcomes                           3
  Dextropropoxyphene                         HLGT                                          Fatal outcomes†                          55
  HLGT                                       Overdoses                                     91                                       
  Nefazodone                                 HLGT                                          Hepatic and hepatobiliary disorders      16
  Ximelagatran/melagatran                    No results were returned                                                               
  Lumiracoxib                                HLGT                                          Hepatic and hepatobiliary disorders      92
  Sitaxentan\*                               PT                                            Hepatitis                                8
  PT                                         Hepatic failure                               6                                        
  Bufexamac                                  SOC                                           Immune systems disorders                 10

\*Centrally authorised drug products. Information available on: <http://www.adrreports.eu>. Other information received by email from EMA.

†The original condition, preceding the fatal outcome is unknown, therefore, there is a possibility of duplicate reporting.

EMA, European Medicines Agency; HLGT, Higher Level Group Term; PT, preferred term; SOC, System Organ Class.

Discussion {#s4}
==========

This study has shown that the strength of evidence used to support the withdrawal of products relied on information recorded from spontaneous reporting together with other pharmacoepidemiological and clinical research studies. All decisions to revoke marketing authorisations described in this study utilised spontaneous case reports, except for the withdrawal of ximelagatran.[@R8] Spontaneous case reporting remains central to pharmacovigilance as it allows for the detection of suspected adverse drug reactions and significant safety signals. However, spontaneous reporting should be used in conjunction with other pharmacovigilance methodologies such as observational studies and clinical trials to further evaluate any such safety signals due to the potential for over and under-reporting, confounding, bias and misclassification. The RCT is commonly assumed to be the gold standard for clinical research[@R9] but adverse drug reactions may not become evident until a medicine is used in the larger population, post-authorisation, where patients are more likely to have comorbidities and other risk factors. The outcome of pharmacoepidemiology studies and the conduct of systematic reviews, even with their limitations particularly bias, confounding and misclassification, can provide useful additional evidence on the nature and frequency of adverse drug reactions. As a direct country comparison, Clarke *et al*[@R4] stated that six products were withdrawn in the UK in between 1999 and 2001, namely grepafloxacin (marketed for 2 years), cisapride (12 years), pumactant (6 years), cerivastatin (4 years), droperidol (30 years) and levacetylmethadol (4 years). The median length of time these drugs remained on the UK market was 5 years (IQR 4--10.5). Droperidol was available for approximately 30 years as it was marketed before the licensing system began in 1971 (personal communication from MHRA (2013)). In contrast, only three products were withdrawn from the UK market between 2009 and 2011; orciprenaline, sibutramine and rosiglitazone marking a 50% reduction in the number of drug products withdrawn over the same time period. The median length of time these products remained on the market was 11 years (IQR 10.5--30). Although the length of time taken to withdraw a drug product appears to have doubled (mainly due to the length of time orciprenaline was available, 49 years) over the 10-year period, the evidence used to aid the decision-making has been heightened. Spontaneous case reporting was used to support the case for withdrawal in five of the six products between 1999 and 2001, while only one RCT was included as evidence.[@R4] In this study, spontaneous case reporting and RCTs were shown to have contributed to all three withdrawn products, which suggests an increase in the level of evidence used to support decisions for drug product withdrawal from the market.

The findings of this study are in line with those of the study conducted by Paludetto *et al*[@R6] in 2012 who observed a shift in the nature of the safety data used as justification for the withdrawal of products in France in the time periods 1998--2004 and 2005--2011. One explanation the authors gave for this change was the implementation of the European Clinical Trial Directive in 2004 and the subsequent analysis of clinical trial safety data by pharmacovigilance experts. The evolution of pharmacovigilance legislation over the past decade is likely to have contributed to the availability of additional data through the conduct of post-marketing safety surveillance allowing regulators and companies to include such information in the drug products safety portfolio. It is difficult to ascertain whether the introduction of RMPs for newly licensed medicinal products has influenced the length of time a drug with safety concerns remains on the market as only two drug products included in this study were marketed after 2005. Rimonabant and sitaxentan were licensed in 2006 and removed from the market in 2008 and 2010, respectively. At the time of authorisation, information was known about the psychiatric side effects of rimonabant[@R10] and liver toxicity associated with sitaxentan[@R11] and the benefit-risk balance deemed to be favourable. However, in the case of rimonabant, as data became available when used in the real-life clinical setting, the risk of obese and overweight patients developing psychiatric side effects was double that of patients taking placebo.[@R10] The marketing authorisation holder voluntarily removed sitaxentan from the market and cancelled ongoing clinical trials as a result of two cases of fatal liver injury.[@R11] During the time period studied, an additional 12 drugs were withdrawn in some but not all EU countries. In some cases, it was not feasible to establish the reasons for the withdrawal, for example, astemizole has been withdrawn from the UK, France and Spain, but information about its availability in other EU countries is difficult to establish. Another example, the NSAID nimesulide, was withdrawn in Spain, Finland, Belgium and Ireland but is still available in 15 EU member states. The EMA had a favourable opinion of the risk-benefit balance after a review of spontaneous reports of epidemiological studies and other published studies in 2010.[@R12] This was in spite of evidence of an increased risk of hepatotoxicity compared with other NSAIDs, although restrictions are in place to limit the number of liver-related side effects. Ultimately, it would seem that there is a disparity in opinion of risk-benefit within the EU between decision-makers at the EMA and various regulatory authorities.

The main limitation of this study was the impact of various language barriers across the EU. Websites of competent authorities are written in their local language and resource constraints did not allow for translations. Only information from the websites of those competent authorities where English and French are spoken locally or an English or French version is available was utilised. This may also have had a bearing on the studies included as evidence in this research as again only English and French publications were included. After a website search, competent authorities and pharmaceutical companies were contacted in order to obtain further information on drug product withdrawals. The response rate from competent authorities was 70% and from pharmaceutical companies 55%. Again, this may have been due to a language barrier problem, but it may also be due to a lack of available information on drugs withdrawn for several years or an unwillingness to share information. Competent authorities or companies may also not have a complete list of products removed from the market. Over time, the way in which drug products have been licensed in the EU has changed considerably. It is relatively easy to determine how products licensed centrally were withdrawn from the market. However, for drugs that have been licensed for a considerable number of years, in countries that have recently joined the EU, and for those that have multiple drug names, it can be very difficult to obtain conclusive, consistent and clear information. The effect of different drug names may have led to potential exclusions of study evidence from our PubMed search strategy as the INN of each drug was used rather than an exhaustive drug name list. Owing to time constraints, it was not possible to conduct a full investigation into why drug products had been removed from the market in some but not all countries and to find detailed information about the decision-making process.

It would be useful to investigate the impact of the introduction of RMPs in a future study. This could be carried out as an investigation of how results from postmarketing studies, conducted as part of RMPs, aid in the assessment of any safety issues. In theory, the introduction of RMPs should expedite post-marketing drug safety decisions.

This study has shown that the strength of evidence has improved during the past 10 years. Indeed, the results show an increased use of case--control studies, cohort studies, RCTs and meta-analyses as justification for the withdrawal of a marketed product. Previously, only one-third of decisions used evidence from observational studies or clinical trials[@R4] but this study showed that they had contributed to decision-making in almost two-thirds of withdrawals. Spontaneous case reports remain the most significant method of pharmacovigilance.
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